Thursday, February 21, 2019 - 5:00pm-6:30pm (ended)
Chevron Auditorium, International House
Dr. Jennifer Doudna, UC Berkeley
Our technological capacity to make changes to genomic data has expanded exponentially since the 2012 discovery of CRISPR-Cas9 as an RNA-programmable genome editing tool. Over the past seven years, this genome editing platform has been used to revolutionize research, develop new agricultural crops, and even promises to cure genetic diseases. However, ethical and societal concerns abound, requiring a thoughtful and ongoing discussion among scientists and stakeholder groups.
Dr. Jennifer Doudna is a Professor in the Department of Chemistry and the Department of Molecular and Cell Biology at UC Berkeley and is Li Ka Shing Chancellor's Professor in Biomedical and Health. She is a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, National Academy of Sciences, and the American Academy of Arts and Sciences. In 2018, Doudna received a Medal of Honor from the American Cancer Society.
Part of the IIS Endowed Elberg Series.